Jacqueline Glascock of Cure SMA Discusses FDA-Approved SMA Treatments & Dissects Combination Therapy

November 17, 2021

Managed Healthcare Executive® recently interviewed Jacqueline Glascock, Ph.D., the director of research programs at Cure SMA, an nonprofit organization in Elk Grove, Illinois, that funds research into spinal muscular atrophy (SMA) and advocates for families and patients. In this video, Glascock discusses SMA and her organization, the three current therapies for the disease, and a combination therapy approach to the disease.

DNA from Saliva has Potential for Detecting SMA

November 15, 2021

Investigators in Japan have developed a new, noninvasive method for screening for spinal muscular atrophy using saliva analyzed with conventional PCR as an alternative to blood-based genetic screening.

Study Looks At Novel Administration of Spinraza

October 14, 2021

A new method for delivering this treatment drug for spinal muscular atrophy offers an option for patients with advanced cases of the disease. But investigators found that the new method may also carry risks of mechanical failure and infection.

Spinal Muscular Atrophy Drug Risdiplam Proves Success in Infants

March 02, 2021

Patients treated with risdiplam at 12 months demonstrated significant improvement in survival and developmental milestones, with 19 of 21 (90%) infants able to survive without permanent ventilation and 7 (41%) infants able to sit without support for at least 5 seconds.